deltatrials
Completed PHASE2 NCT00003111

Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

Phase II Clinical and Laboratory Study of Irinotecan/Cisplatin Chemotherapy Followed by Surgery in Stage III NSCLC

Sponsor: National Cancer Institute (NCI)

Conditions Lung Cancer
Interventions carboplatin cisplatin irinotecan hydrochloride neoadjuvant therapy paclitaxel radiation therapy surgical procedure
Updated 5 times since 2017 Last updated: Jul 23, 2013 Started: Apr 30, 1997 Primary completion: Apr 30, 2004 Completion: Apr 30, 2004

This PHASE2 trial investigates Lung Cancer and is currently completed. National Cancer Institute (NCI) leads this study, which shows 5 recorded versions since 1997 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Apr 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • Yale University
Data source: Yale University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New Haven, United States